To test whether IL-1β was responsible for increased disease severity, or was a consequence of increased inflammatory signaling, we monitored the extent and kinetics of lesion development in RAG+CD8 mice that were treated with anti-IL-1R, anti-IL-1β or anti-IL-1α monoclonal antibodies two weeks after infection. This evidence concerns the gene IL1A and infection.